List of Excipients in Branded Drug LEUCOVORIN CALCIUM

« Back to Dashboard

Generic Drugs Containing LEUCOVORIN CALCIUM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	leucovorin calcium	0054-4496	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	leucovorin calcium	0054-4496	CROSCARMELLOSE SODIUM
Hikma Pharmaceuticals USA Inc	leucovorin calcium	0054-4496	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	leucovorin calcium	0054-4496	POVIDONE
Hikma Pharmaceuticals USA Inc	leucovorin calcium	0054-4496	SILICON DIOXIDE
Hikma Pharmaceuticals USA Inc	leucovorin calcium	0054-4496	STARCH, CORN

What are the Most Frequently-Used Excipients in LEUCOVORIN CALCIUM?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
11	CELLULOSE, MICROCRYSTALLINE
11	CROSCARMELLOSE SODIUM
1	D&C YELLOW NO. 10
1	D&C YELLOW NO. 10 ALUMINUM LAKE
1	FD&C BLUE NO. 1--ALUMINUM LAKE

Leucovorin Calcium Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Leucovorin calcium is a mature generic active pharmaceutical ingredient with limited composition-of-matter protection and substantial price competition. Commercial value is shifting from API differentiation to formulation performance, hospital supply reliability, ready-to-use injectable presentations, pediatric and liquid dosage forms, and excipient systems that improve stability, compatibility, and administration efficiency.

The strongest opportunities are preservative-free sterile injectables, ready-to-administer bags or syringes, concentrated hospital presentations, low-excipient oral products, and differentiated formulations for patients who cannot swallow tablets. Patent barriers are generally low, but regulatory execution, sterile manufacturing, shortage resilience, and institutional contracting remain meaningful entry barriers.

What is leucovorin calcium and where is it used?

Leucovorin calcium is the calcium salt of folinic acid, also called calcium folinate. It is a reduced folate that does not require dihydrofolate reductase activation. FDA-approved uses include rescue after high-dose methotrexate, reduction of methotrexate toxicity, and use with fluorouracil in colorectal cancer treatment. Some products are also labeled for treatment of folate-deficiency megaloblastic anemia when oral therapy is not feasible [1-3].

Leucovorin calcium is marketed primarily in:

Dosage form	Typical use	Commercial characteristics
Oral tablets	Methotrexate rescue, folate-related indications	Low manufacturing complexity; price-sensitive generic market
Sterile injection	High-dose methotrexate rescue and oncology protocols	Higher regulatory and manufacturing barriers
Powder for injection	Institutional oncology use	Longer shelf-life potential; reconstitution burden
Oral solution or suspension	Pediatric, geriatric, and dysphagia populations	Formulation and stability differentiation
Ready-to-use infusion	Hospital and oncology pharmacy use	Workflow, safety, and waste reduction opportunity

Leucovorin calcium is a small molecule, not a biologic. Biosimilar competition is therefore not relevant. The competitive threat comes from abbreviated new drug applications, authorized generics, contract-manufactured products, and institutional substitutions among generic suppliers.

What excipients are used in leucovorin calcium products?

The excipient profile depends heavily on the route and dosage form. Injectable products generally use a minimal formulation because leucovorin calcium is administered to medically complex patients, often during chemotherapy or methotrexate rescue.

Injectable excipients

Common injectable formulation elements include:

• Water for injection
• Sodium chloride for isotonicity
• Sodium hydroxide or hydrochloric acid for pH adjustment
• Nitrogen or another inert headspace gas in selected presentations
• Container and closure components, including elastomeric stoppers and vial coatings

Commercial labels should be reviewed product by product because excipient composition differs among manufacturers and presentations. Some products are supplied as solutions, while others are supplied as sterile powders requiring reconstitution [1, 2].

The principal excipient risks are not usually pharmacologic toxicity. They are:

1. Chemical degradation of folinate under unsuitable pH or storage conditions.
2. Particulate formation or precipitation after dilution.
3. Sorption to infusion bags or tubing.
4. Container-closure interaction.
5. Microbial contamination during aseptic preparation.
6. Compatibility problems with fluorouracil or other oncology agents.

A low-excipient, preservative-free formulation is generally commercially attractive for intravenous use. Benzyl alcohol and other antimicrobial preservatives can create avoidable concerns in neonates, pediatric patients, and high-frequency hospital use.

Oral-tablet excipients

Oral tablets may use conventional excipients such as:

• Lactose or another diluent
• Microcrystalline cellulose
• Pregelatinized starch
• Crospovidone or croscarmellose sodium
• Povidone
• Colloidal silicon dioxide
• Magnesium stearate
• Film-coating polymers, pigments, and plasticizers

The commercial issue is not simply whether an excipient is technically acceptable. Lactose intolerance, milk-protein concerns, gluten perceptions, dye sensitivity, and excipient restrictions in pediatric or institutional formularies can influence product selection.

A lactose-free, dye-free, low-allergen tablet can support formulary differentiation, but the opportunity is limited unless the supplier can obtain reliable reimbursement or institutional preference. In a mature generic market, excipient differentiation rarely supports a large price premium without a measurable clinical or operational benefit.

Oral-liquid excipients

An oral liquid requires greater formulation engineering than a conventional tablet. Relevant excipient functions include:

• Buffering and pH control
• Sweetening and flavor masking
• Suspending agents
• Wetting agents
• Preservatives, if justified
• Chelating agents
• Antioxidants
• Osmolality adjustment
• Protection from light and oxygen

Potential ingredients include sucrose, sorbitol, glycerin, hydroxyethylcellulose, xanthan gum, citrate or phosphate buffers, and flavor systems. The selection must account for pediatric tolerability, diabetic use, dental exposure, microbial control, and the chemical stability of folinate.

An alcohol-free, sugar-free, dye-free oral solution would have a clearer commercial position than a standard flavored product. The critical development requirement is a validated beyond-use or in-use period after opening, together with dose-measurement accuracy.

What excipient strategy is best for injectable leucovorin calcium?

The preferred strategy is a minimal, preservative-free aqueous formulation supported by robust pH control, low particulate generation, and validated dilution compatibility.

Formulation priorities

Priority	Development objective	Commercial benefit
Chemical stability	Control pH, oxygen exposure, and light	Longer shelf life and lower waste
Physical stability	Prevent precipitation and visible or subvisible particles	Fewer pharmacy rejects
Compatibility	Validate common infusion fluids, bags, and tubing	Easier hospital adoption
Microbiological quality	Sterile, preservative-free unit doses	Reduced safety concerns
Packaging	Use low-sorption container systems	Better delivered dose and stability
Concentration	Offer practical strengths for oncology protocols	Less manipulation and fewer preparation steps

The formulation should be evaluated against the actual hospital use environment, not only against storage conditions. Methotrexate rescue often involves protocol-driven dosing, repeated administration, and pharmacy compounding. A formulation that minimizes withdrawals, transfers, dilution steps, and discarded partial vials can have greater commercial value than a marginal improvement in nominal shelf life.

Ready-to-use presentations

Ready-to-use bags, prefilled syringes, and pharmacy-ready vials are the most credible injectable opportunities. These products can reduce:

• Aseptic compounding workload
• Calculation and preparation errors
• Occupational exposure during manipulation
• Partial-vial waste
• Inventory complexity

A ready-to-use product may require a higher level of container-closure, extractables and leachables, transport, and stability work. The business case depends on whether hospitals will pay for workflow savings and supply reliability.

What formulations are protected by patents?

Leucovorin calcium itself is a mature active ingredient. Basic composition-of-matter exclusivity is not a meaningful barrier to new generic development. The remaining intellectual-property opportunity is more likely to involve:

• Specific injectable concentrations
• Stabilized aqueous formulations
• Lyophilized compositions
• Ready-to-administer containers
• Premixed infusion systems
• Oral liquids with defined excipient ratios
• Modified-release or taste-masked oral dosage forms
• Combination products
• Manufacturing processes
• Container-closure systems
• Dosing devices and pharmacy-administration systems

A formulation patent must provide more than a routine excipient substitution. Stronger claims generally require a defined stability advantage, unexpected compatibility result, improved reconstitution time, reduced degradation product formation, or a specific administration benefit.

A product that uses conventional excipients at conventional concentrations is more vulnerable to obviousness challenges. Proprietary value is stronger where the formulation solves a documented problem, such as prolonged room-temperature stability, reduced precipitation after dilution, or reliable dose delivery from a multidose system.

What is the Orange Book status of leucovorin calcium?

Leucovorin calcium products are regulated as small-molecule prescription drugs. The FDA Orange Book is the relevant reference for listed patents, therapeutic equivalence, and exclusivity; biosimilar databases do not apply [4].

The commercial patent position is generally mature:

Issue	Assessment
Basic API patent	Expired or commercially irrelevant
Generic entry	Established
ANDA pathway	Primary route for conventional tablets and injections
180-day generic exclusivity	Possible only for qualifying first applicants and product-specific filings
Formulation patents	Potentially relevant for differentiated products
Method-of-use patents	Narrow opportunity; depends on claim scope and labeling
Biosimilar risk	None
Orange Book patent risk	Must be assessed against the specific reference-listed drug and product code

An applicant should not assume that an old API has no patent risk. A later patent may cover a formulation, concentration, container, method of use, or manufacturing process. The practical risk is product-specific and should be assessed using the current Orange Book, FDA labels, patent databases, and litigation records [4-6].

When does leucovorin calcium lose exclusivity?

Leucovorin calcium lost meaningful basic-drug exclusivity many years ago. Conventional oral and injectable products are already exposed to generic competition. Current commercial protection, if any, is more likely to arise from product-specific formulation patents, regulatory exclusivity, supply contracts, or manufacturing scarcity than from the active ingredient.

FDA approval of a generic product does not create broad market exclusivity. A first applicant may obtain 180-day exclusivity in a qualifying ANDA pathway, but that protection is limited and does not prevent all forms of competition. A formulation patent may also delay entry only if it is listed, enforceable, and successfully asserted.

For investment purposes, the key question is not the expiration date of leucovorin calcium itself. It is whether a differentiated presentation has a valid, enforceable barrier that competitors cannot readily design around.

What Paragraph IV challenges and patent litigation affect leucovorin calcium?

Paragraph IV risk is generally limited for standard leucovorin calcium tablets and injections because the products are mature and genericized. The more relevant risk arises when a sponsor develops a new formulation or delivery system and seeks to protect it with patents.

Potential Paragraph IV targets include:

• Patents covering a ready-to-use injectable concentration
• Patents covering a stability-enhancing excipient combination
• Patents covering a premixed oncology infusion
• Patents covering an oral liquid or pediatric formulation
• Patents covering a specific manufacturing or sterilization process

A generic applicant challenging a listed patent would typically certify that the patent is invalid, unenforceable, or will not be infringed. The reference product, listed patents, and filing history must be checked in current FDA and court records because patent status can change through litigation, disclaimers, settlements, or delisting [4, 6].

No broad, industry-defining patent dispute is generally associated with the legacy leucovorin calcium market. Litigation exposure is more likely to be transaction-specific and tied to a newer formulation.

What manufacturing and IP barriers exist?

Sterile manufacturing is the main practical barrier for injectable leucovorin calcium. Key requirements include:

• Validated aseptic processing
• Sterilizing filtration or validated terminal sterilization, where feasible
• Container-closure integrity
• Particulate and endotoxin control
• Extractables and leachables assessment
• Photostability studies
• Stability after dilution
• Transport validation
• Process controls for calcium-containing solutions

A powder-for-injection product may reduce some liquid stability problems but adds reconstitution requirements and potential medication-preparation errors. A liquid product may offer greater convenience but require more intensive stability and container-closure work.

The manufacturing strategy should also address API supply. Leucovorin calcium is a relatively specialized folate API. A second qualified API source, dual-site fill-finish capability, and inventory of critical packaging components can create a stronger commercial position than a nominally differentiated excipient system.

Which companies are competing in leucovorin calcium?

Competition includes generic injectable and oral suppliers, hospital-focused manufacturers, specialty distributors, and contract development and manufacturing organizations. The relevant competitive factors are:

• FDA approval status
• Product availability by strength and package size
• Backorder history
• National wholesaler coverage
• 340B pricing
• GPO contracting
• Hospital pharmacy preference
• Shelf life
• Ready-to-use availability
• Product quality history

Public companies generally do not disclose revenue for leucovorin calcium separately. Revenue exposure should therefore be estimated from product-level sales data, shipment data, contract awards, and company filings rather than corporate oncology revenue totals.

The most attractive competitive position is a reliable supplier with a differentiated presentation and enough scale to support hospital contracts. A low-cost tablet launch alone is unlikely to create durable value.

What commercial opportunities exist for leucovorin calcium?

1. Ready-to-administer oncology products

Premixed bags or syringes can reduce pharmacy labor and preparation risk. This is the clearest opportunity for formulation and packaging differentiation.

2. High-concentration injectable presentations

A higher concentration may reduce vial count and preparation volume. Development must demonstrate acceptable stability, viscosity, injectability, dilution behavior, and dosing accuracy.

3. Pediatric oral liquid

An alcohol-free, sugar-free, dye-free liquid could address patients unable to swallow tablets. Taste, dose accuracy, microbiological stability, and post-opening stability determine commercial viability.

4. Excipient-reduced tablets

Lactose-free and dye-free tablets can serve institutional formularies and patients with excipient restrictions. This is a modest opportunity unless supported by distribution or reimbursement advantages.

5. Dual-source hospital supply

Hospitals may value dependable supply more than small differences in tablet excipients. A supplier that combines domestic fill-finish capacity with a qualified backup source can compete effectively during shortages.

6. Combination and protocol-support products

Leucovorin calcium is administered within structured oncology protocols. Packaging that groups doses, provides clear labeling, or supports pharmacy workflow may produce commercial value, although combination claims and regulatory requirements must be evaluated carefully.

How strong is the patent estate for leucovorin calcium?

The legacy patent estate is weak as a barrier to conventional generic entry. The stronger opportunities are formulation-specific and operational.

Protection type	Relative strength
API composition	Low
Conventional tablet composition	Low
Standard aqueous injection	Low to moderate
Novel stability system	Moderate, if supported by unexpected data
Ready-to-use container system	Moderate
Pediatric liquid	Moderate if stability and dosing advantages are demonstrated
Manufacturing process	Variable
Distribution and supply capability	Commercial rather than patent protection

A sponsor should invest in formulation patents only where the development program produces measurable advantages that can be claimed narrowly and defended technically.

How does leucovorin calcium compare with folic acid and other folates?

Leucovorin calcium differs from folic acid in mechanism, clinical use, and commercial setting.

Attribute	Leucovorin calcium	Folic acid
Chemical class	Reduced folate	Oxidized folate
Principal use	Methotrexate rescue and fluorouracil modulation	Nutritional folate supplementation
Market channel	Oncology, hospital, prescription	Retail, prenatal, prescription, and dietary supplement
Injectable opportunity	Material	Limited
Hospital workflow value	High	Low
Patent opportunity	Formulation and delivery	Usually limited
Generic competition	Strong	Very strong

Leucovorin calcium has a smaller but more specialized market. That supports premium commercial opportunities in hospital workflow, sterile supply, and dosing convenience rather than mass-market consumer positioning.

Key Takeaways

• Leucovorin calcium is a mature small-molecule generic with no meaningful biosimilar risk.
• Basic API exclusivity is not the main commercial barrier.
• Injectable formulation, packaging, stability, and supply reliability create the strongest opportunities.
• Preservative-free, low-excipient sterile products are preferred for hospital and oncology use.
• Ready-to-use bags, prefilled syringes, and concentrated presentations can reduce pharmacy labor and waste.
• Pediatric oral liquids require meaningful work on taste, microbial control, dosing accuracy, and post-opening stability.
• Conventional excipient substitutions are unlikely to support durable patent protection without unexpected technical results.
• Paragraph IV risk is more relevant to new formulation products than to legacy tablets and injections.
• Revenue is not usually disclosed at the product level, so commercial exposure requires product-specific market and contracting analysis.
• The strongest defensibility may combine formulation IP, sterile manufacturing capability, dual sourcing, and hospital distribution.

FAQs

Is leucovorin calcium the same as folinic acid?

Leucovorin calcium is the calcium salt of folinic acid, also called calcium folinate. The terms are often used interchangeably in clinical and commercial settings, although formulations may contain different salts or presentations.

Can leucovorin calcium be formulated without preservatives?

Yes. Preservative-free injectable formulations are commercially established and generally appropriate for single-dose sterile products. The formulation must still meet sterility, stability, container-closure, and particulate requirements.

Is there a commercial opportunity for an injectable leucovorin calcium shortage product?

Potentially. The opportunity depends on FDA shortage status, approved manufacturing capacity, procurement contracts, API availability, and the ability to produce compliant sterile product at sufficient scale.

Can leucovorin calcium tablets be made lactose-free?

Yes. Lactose can be replaced with alternatives such as microcrystalline cellulose, mannitol, or other suitable diluents. The replacement must preserve tablet hardness, dissolution, stability, and content uniformity.

Are leucovorin calcium formulation patents easy to obtain?

No. A patent application can be filed for a new formulation, but enforceable protection generally requires a defined composition and technical evidence supporting novelty and nonobviousness. Routine excipient substitution is vulnerable to validity challenges.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Leucovorin calcium injection prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). DailyMed: Leucovorin calcium tablets prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2023). FDA-approved drug products containing leucovorin calcium. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2019). Questions and answers on patents and exclusivity. https://www.fda.gov/drugs/development-approval-process-drugs

6. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search. https://www.uspto.gov/patents/search.